Mylan, Theravance to partner on nebulized COPD drug

Mylan will spend $45m up front and pay up to $220m in milestone fees plus royalties to co-develop TD-4208, Theravance Biopharma's once-daily long-acting muscarinic antagonist (LAMA) delivered by a nebulizer for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.